Genelux Corp.
GNLX
Genelux is a late clinical-stage biopharmaceutical company focused on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat tumor types. Our clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient's tumor neoantigens.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (FY)
$8K
Net Income (TTM)
-$36M
▼ -7.6% YoY
Op. Margin
-415175.00%
▼ -18975.0pp YoY
ROIC
-148.71%
▼ -28.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$29M
▼ -22.0% YoY
Op. Cash Flow (TTM)
-$25M
▼ -19.0% YoY
Net Debt
-$16M
Net Cash Position
Cash & Equiv.
$19M
3Y CAGR: -91.0%
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with GNLX
Held by ETFs
GNLX is in 1 US ETF. The largest of them, with GNLX's weight in each:
Genelux (GNLX) in four numbers
Questions about Genelux
Is Genelux (GNLX) overvalued?
At $1.96, Genelux's price is 575793% above the $0.00 a share fair value that Intrinsiqq's calculator gets from its revenue. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.
What is Genelux's fair value?
Intrinsiqq's calculator puts Genelux's fair value at $0.00 a share. It grows revenue per share 0% a year for 5 years, applies an exit P/S of 3.1, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $0.00. Every input can be changed on the Intrinsic Value tab.
Is Genelux a high-quality business?
Genelux scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 6 checks computed from SEC filings. Its best check is net debt at -$16M, and its weakest is return on capital at -148.7%. The Quality tab shows every check against its target.
Does Genelux (GNLX) pay a dividend?
No. Genelux (GNLX) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 11 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 6 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in GNLX's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing GNLX
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.